May 26, 2024

Serum (‐2)proPSA/freePSAratio, (‐2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate‐specific antigen 2–10 ng/mL

Key Points

Key points are not available for this paper at this time.

Abstract

There is a strong clinical need to fill the gap of identifying clinically significant prostate cancer (csPCa) in men with prostate-specific antigen (PSA) gray zone values. Promising, but not definitive results have been obtained using PSA derivatives such as prostate health index (PHI) and PHI density (PHID) and the percentage (-2)proPSA/free PSA (%p2PSA/fPSA). Thus, this study aimed to compare the diagnostic value of PHI, PHID, %proPSA/fPSA, and (-2)proPSA/freePSA density (-2pPSA/fPSAD) for csPCa in the patients with PSA within 2-10 ng/mL.

Bookmark

Cite This Study

Ferro et al. (Sun,) studied this question.

synapsesocial.com/papers/68e6859ab6db64358760e616 https://doi.org/https://doi.org/10.1002/pros.24752

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark